ライフサイエンスコーパス: claudication

1 ambulation, which is known as "intermittent claudication".

2 uality of life in patients with intermittent claudication.

3 D participants with and without intermittent claudication.

4 patency rates of nearly 80% in patients with claudication.

5 %, and 0.5%, respectively, for patients with claudication.

6 eral arterial disease (PAD) and intermittent claudication.

7 ons militate against active intervention for claudication.

8 lity of life [QOL] in patients with arterial claudication.

9 ulceration or amputation, and improvement of claudication.

10 schemic events in patients with intermittent claudication.

11 ife, and determined the prevalence of venous claudication.

12 sical activity in patients with intermittent claudication.

13 ng performance in patients with intermittent claudication.

14 alvage, as well as those being evaluated for claudication.

15 has some effect on dementia and intermittent claudication.

16 15 patients (20 limbs) evaluated because of claudication.

17 atients with moderate-to-severe intermittent claudication.

18 peripheral arterial disease had intermittent claudication.

19 eral arterial disease (PVD) and intermittent claudication.

20 sed for patients with disabling intermittent claudication.

21 tolerated for the treatment of intermittent claudication.

22 nt of stable, moderately severe intermittent claudication.

23 ble treatment for patients with intermittent claudication.

24 dity, including the symptoms of intermittent claudication.

25 > 50 years, awaiting surgery for neurogenic claudication.

26 l revascularization procedures performed for claudication.

27 walking that are not consistent with classic claudication.

28 symptoms included presyncope and upper limb claudication.

29 re, stroke, incident angina, or intermittent claudication.

30 e common in the population than intermittent claudication.

31 who have exertional leg symptoms other than claudication.

32 are not consistent with classic intermittent claudication.

33 d as a first-line treatment for intermittent claudication.

34 f their limb symptoms of classic or atypical claudication.

35 e role for revascularization in intermittent claudication.

36 prove mobility in patients with intermittent claudication.

37 ocyte adhesion in patients with intermittent claudication.

38 ear in unselected patients with intermittent claudication.

39 was found for patients with the diagnosis of claudication.

40 t may warrant further study in patients with claudication.

41 nd December 2009 for the purpose of treating claudication.

42 May 2010 and February 2013 with intermittent claudication.

43 ive treatment for patients with intermittent claudication.

44 h peripheral artery disease and intermittent claudication.

45 ascular events in patients with intermittent claudication?

46 vice group) or among those with intermittent claudication (10.9% [44 patients] and 9.4% [38 patients]

47 of 579 lesions were treated in 275 patients (claudication 101 patients (36.7%) and critical limb isch

48 PVI than for LEB in patients presenting with claudication (12.3+/-2.7% and 19.0+/-3.5% at 1 and 3 yea

49 Among patients with intermittent claudication, 24-week treatment with ramipril resulted i

50 erative LOS was shorter in ERP patients with claudication (3 vs 5 days, P = 0.01), rest pain (5 vs 6

51 02] and an increase in revascularization for claudication [3.7% (1.7%-5.6%), P = 0.01].

52 were asymptomatic, 22% were associated with claudication, 3% were associated with rest pain, and 1%

53 ventions between 2001 and 2006 performed for claudication (46.3%) or limb-threatening ischemia (52.7%

54 senting limbs (mean patient age 66.4 yo; 43% claudication, 57% limb-threatening ischemia), 107 were t

55 ing ischemia (1480 patients) or intermittent claudication (809 patients).

56 A history of scalp tenderness and jaw claudication a week before visual symptoms was reported

57 In patients with new or worsened claudication, a 10-point change in PAQ summary score rep

58 Among adults with PAD and intermittent claudication, a home-based, walking exercise behavior ch

59 Among patients with intermittent claudication after 1 year of follow-up, a combination th

60 al artery disease patients with intermittent claudication after a home-based exercise program, a supe

61 Compared with participants with intermittent claudication, always asymptomatic PAD participants had s

62 including 36 PAD patients with intermittent claudication and 20 matched controls, underwent contrast

63 74.2 non-Hispanic White), 20 769 (38.3%) had claudication and 33 411 (61.7%) had CLTI per gold standa

64 tics compared with persons with intermittent claudication and a sedentary, asymptomatic, age-matched

65 ing PAD at baseline if they had intermittent claudication and an ankle brachial index of <0.85, or if

66 ral artery disease (n=3787) had a history of claudication and an ankle-brachial index of <0.85 or pri

67 mity pain, which may present as intermittent claudication and atypical leg pain, and, in more severe

68 Revision, codes used to distinguish between claudication and chronic limb-threatening ischemia (CLTI

69 ctive endovascular therapy for patients with claudication and CLI with a low mortality, low complicat

70 Gold standard claudication and CLTI diagnoses were determined using VQ

71 n, codes can be used to discriminate between claudication and CLTI in claims data.

72 of LEB and PVI in patients with symptomatic claudication and critical limb ischemia.

73 A total of 82 patients with claudication and infrainguinal peripheral artery disease

74 roaches to clinical studies in subjects with claudication and ischemic ulceration, with an emphasis o

75 s with clinical manifestations of PAD (e.g., claudication and limb ischemia) have limited treatment o

76 is not useful in patients with intermittent claudication and PAD.

77 association of infrapopliteal procedures for claudication and patient race with 1-year amputation was

78 he observed association between intermittent claudication and rhinitis.

79 n conjunction with systemic features such as claudication and syncope is vital for early diagnosis.

80 nd secondary branches of the aorta may cause claudication and tissue gangrene, whereas aortitis may l

81 and prolong walking distance for those with claudication and to reduce amputation rates among those

82 e were associated with an increased risk for claudication and were included in the profile.

83 troke), and 3) peripheral vascular (arterial claudication and/or gangrene or significant tissue loss

84 enrolled 1535 participants with intermittent claudication and/or ischemic rest pain caused by femorop

85 according to the presence or absence of jaw claudication and/or visual abnormalities, fever, concomi

86 dence of ischemic symptoms, indicated by jaw claudication and/or visual symptoms, typically expressed

87 nderwent LER, 3,478 (80.6%) were treated for claudication, and 1,342 (31.1%) received DCDs.

88 patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia.

89 ions of GCA, such as ocular involvement, jaw claudication, and aortic arch syndrome.

90 rtality, total cardiovascular disease (CVD), claudication, and congestive heart failure (CHF).

91 At 1 year, patients were asymptomatic for claudication, and duplex assessment demonstrated lack of

92 nosis or occlusion, symptoms of intermittent claudication, and maximum walking distance of > or = 30

93 an clinical trials as treatments for angina, claudication, and stroke.

94 ng in skeletal muscle ischemia, intermittent claudication, and, in more severe stages of disease, lim

95 tion; 5% angina pectoris; 2.3%, intermittent claudication; and 7%, a carotid bruit.

96 In patients with intermittent claudication, antiplatelet therapies are associated with

97 therapy in patients with lifestyle-limiting claudication are often underutilized before referral for

98 ed at regular examinations, new intermittent claudication assessed by annual surveillance, or PAD-rel

99 s who were asymptomatic or had mild/moderate claudication at enrollment had no change in symptom clas

100 aire in patients with new-onset or worsening claudication at presentation and 3, 6, and 12 months lat

101 ion, coronary insufficiency, angina, stroke, claudication) at 50 years of age.

102 allel-design study included 354 persons with claudication attributable to peripheral arterial disease

103 ial in patients with atherosclerotic PVD and claudication, bFGF was well-tolerated.

104 e most common symptom of PAD is intermittent claudication, but noninvasive measures, such as the ankl

105 ded as first-line treatment for intermittent claudication by recent guidelines.

106 Many patients with claudication can be treated by exercise and medical ther

107 Patients with intermittent claudication carry a high risk for cardiovascular compli

108 190 patients with intermittent claudication caused by infra-inguinal atherosclerosis we

109 Neurogenic claudication, caused by lumbar spinal stenosis, is the m

110 Intermittent claudication causes pain on walking, has no tissue loss,

111 ysis with subgroup analysis for intermittent claudication, chronic limb-threatening ischemia, and sec

112 ness of combination therapy for intermittent claudication, compared with supervised exercise only.

113 of those with prior I-FDVT developed venous claudication compelling interruption of walking in 15.4%

114 Intermittent claudication, consisting of exertional calf pain that do

115 ated to the 3 main clinical presentations of claudication, critical limb ischemia, and acute limb isc

116 Both groups were encouraged to walk to claudication daily.

117 alation trial was conducted in patients with claudication demonstrating ankle/brachial index <0.8.

118 riteria included age > or =40 years, initial claudication distance (ICD) on treadmill (12.5% incline,

119 lth-related quality of life and intermittent claudication distance after 1 year in patients with stab

120 t was the change at 6 months in the absolute claudication distance as assessed by the Skinner-Gardner

121 Although absolute claudication distance improved in both L-arginine- and p

122 Intermittent claudication distance improved significantly in the inva

123 ed ICD and maximum distance walked (absolute claudication distance, or ACD).

124 o determine initial (ICD) and absolute (ACD) claudication distances, and quality of life assessment (

125 r age, sex, initial [ICD] and absolute [ACD] claudication distances, pressure indices [ABI], poplitea

126 ular tenderness, and ischemic symptoms (limb claudication, dizziness, angina, and renovascular hypert

127 r 6 months in 133 subjects with intermittent claudication due to PAD in a single-center setting.

128 Intermittent claudication due to peripheral arterial occlusive diseas

129 th unilateral exercise-limiting intermittent claudication during 2 qualifying treadmill tests, with p

130 h can occur in the condition of intermittent claudication during exertion, an exaggerated vasoconstri

131 went femoropopliteal index interventions for claudication, endovascular procedures were associated wi

132 The durability of claudication exercise interventions merits its considera

133 Patients with claudication experience significant disability, owing to

134 peripheral artery disease with intermittent claudication (Fontaine stage IIa, able to walk >200 m) a

135 d to compute the probability of intermittent claudication for specified levels of risk factors.

136 tients with advanced CVD (CEAP3-6 +/- venous claudication) for chronic obliteration of the I-F (+/-IV

137 and 6 machine-learning models to distinguish claudication from CLTI.

138 ts who underwent index revascularization for claudication from January 1, 2016, to December 31, 2019.

139 followed 255 male patients with intermittent claudication from the CAVASIC Study during 7 years for o

140 oronary artery bypass graft surgery, stroke, claudication, gangrene, or tissue loss and/or peripheral

141 arterial disease (PAD) without intermittent claudication have been established as beneficial.

142 Current treatment strategies for claudication have limitations.

143 index, diabetes mellitus, sex, intermittent claudication, heart rate, estimated glomerular filtratio

144 etween respiratory diseases and intermittent claudication (i.e. pain in the leg during walking that d

145 se patients included those with intermittent claudication (IC) (n = 23) and critical limb ischemia (C

146 ies in patients presenting with intermittent claudication (IC) and critical limb ischemia (CLI).

147 but it remains unclear whether intermittent claudication (IC) incidence and mortality rates have cha

148 Intermittent claudication (IC) is associated with an increased risk o

149 Importance: Intermittent claudication (IC) is the most common presentation of inf

150 imal endovascular management of intermittent claudication (IC) remains disputed.

151 or have leg symptoms other than intermittent claudication (IC).

152 sease, which often manifests as intermittent claudication (IC).

153 Intermittent claudication identifies persons at increased risk for de

154 consequences of PAD include pain on walking (claudication), impaired functional capacity, pain at res

155 available for the treatment of intermittent claudication in 2015 and 2012, respectively.

156 Indications for stent placement were claudication in 312 (62%), rest pain in 107 (21%), ulcer

157 cluding 190 adults with PAD and intermittent claudication in 6 hospitals in the United Kingdom betwee

158 reatment to improve symptoms of intermittent claudication in patients with PAD.

159 taglandin I(2) analogue, in the treatment of claudication in patients with peripheral arterial diseas

160 ing to vascular clinics with new or worsened claudication in the US cohort of the PORTRAIT (Patient-C

161 The prevalence of intermittent claudication in these groups was, respectively, 2.5%, 3.

162 PACE (Patients With Intermittent Claudication Injected With ALDH Bright Cells) is a Natio

163 nt index interventions for the indication of claudication into the multicenter national registry Vasc

164 95% CI, 27-60%) of patients developed venous claudication ipsilateral to I-FDVT (ICD: 130 m, range 10

165 Claudication is a common and disabling symptom of periph

166 Claudication is associated with walking impairment, but

167 r invasive revascularization in intermittent claudication is low or very low.

168 enefit of revascularization for intermittent claudication is poorly understood.

169 Intermittent claudication is relatively common in elderly patients an

170 s of peripheral artery disease, intermittent claudication, leg revascularisation, and leg amputation)

171 ted with the age of the patients but not the claudication-limited exercise performance of the patient

172 in peripheral arterial disease patients with claudication-limited exercise performance.

173 isease (PAD) have exercise limitation due to claudication-limited pain and metabolic alterations in s

174 al limb ischemia (CLI) or lifestyle-limiting claudication (LLC).

175 Absence of neurogenic claudication (LR, 0.23; 95% CI, 0.17-0.31) decreased the

176 in (LR, 6.3; 95% CI, 3.1-13), and neurogenic claudication (LR, 3.7; 95% CI, 2.9-4.8).

177 erity of arterial stenosis, exercise induced claudication, malperfused tissue precluding normal heali

178 level standards incentivizing evidence-based claudication management may support equitable outcomes a

179 undred sixty-five patients with intermittent claudication (mean, 65.3 [SD, 6.7] years) were administe

180 gh adherence and is efficacious in improving claudication measures similar to a standard supervised e

181 12 patients undergoing revascularization for claudication (median [IQR] age, 71 [66-76] years; 3850 f

182 For intermittent claudication, mortality was lower after paclitaxel devic

183 Patients with intermittent claudication (n = 897) were randomized to receive either

184 , worsening hypertension (n=1), intermittent claudication (n=1) and wound infection (n=1).

185 to leg symptom groups including intermittent claudication (n=215) and always asymptomatic (participan

186 , Clinical Modification, diagnosis codes for claudication (N=8128), rest pain (N=3056), and ulceratio

187 ilure), major adverse limb events (new-onset claudication, new-onset critical limb ischemia, EVT, and

188 ith PAD have neither classic symptoms of leg claudication nor threatened limbs but have an extraordin

189 d complicated CVD (C3-C6) ameliorates venous claudication, normalizes outflow, and enhances calf musc

190 Incapacitating venous claudication noted in 62.5% (10 of 16, 95% CI, 35.8%-89.

191 Intermittent claudication occurred in a total of 381 men and women.

192 Both exercise programs increased claudication onset time (P<0.001) and peak walking time

193 Primary outcome measures included claudication onset time and peak walking time obtained f

194 The changes in claudication onset time and peak walking time were simil

195 Secondary end points included changes in claudication onset time and quality of life, assessed wi

196 ly significant improvements in the treadmill claudication onset time as compared with placebo.

197 Improvement in claudication onset time was greater for SE compared with

198 s, including DeltaPWT, ankle-brachial index, claudication onset time, and quality-of-life measures (S

199 The secondary end point was change in claudication onset time, and tertiary end points include

200 There were no significant differences in claudication onset time, ankle-brachial index, or qualit

201 s in the ABI, WIQ distance and speed scores, claudication onset time, or mental or physical component

202 Peak walking time, claudication onset time, Walking Impairment Questionnair

203 rwent a peripheral vascular intervention for claudication or CLTI in the US Medicare-matched VQI-VISI

204 wer extremity arterial disease (intermittent claudication or CLTI).

205 Patients presenting with either intermittent claudication or critical limb ischemia undergoing FP int

206 , 476 patients with symptomatic intermittent claudication or ischemic pain while at rest and angiogra

207 Patients with claudication or ischemic rest pain (Rutherford class 2-4

208 rial in which 331 patients with intermittent claudication or ischemic rest pain attributable to super

209 e patient with symptom-limiting intermittent claudication or limb-threatening ischemia begins with un

210 ntly developed symptomatic PAD (intermittent claudication or need for revascularization) and in an eq

211 pheral arterial disease than is intermittent claudication or other leg symptoms.

212 ients is not forward-stooping but neurogenic claudication or pain, lumbar decompression without addin

213 One hundred two patients with claudication or rest pain were randomly assigned 1:1 to

214 ts were defined as bypass, major amputation, claudication, or percutaneous angioplasty.

215 mary end point event or angina, intermittent claudication, or transient ischemic attack; and (2) all-

216 s were directly related to the prevalence of claudication (p = 0.001) and aortic aneurysm (p = 0.02).

217 oncalf pain, atypical calf pain, and classic claudication (P=0.002).

218 compared with nonusers for the diagnosis of claudication (P=0.003), a similar trend for rest pain (P

219 mented response occurred before the onset of claudication pain and was attenuated by approximately 50

220 ed of intermittent walking to nearly maximal claudication pain for 12 weeks.

221 Claudication pain, linked with low blood flow, can be pa

222 al arterial disease include pain on walking (claudication), pain at rest, and loss of tissue integrit

223 iovascular disease, cerebrovascular disease, claudication, peripheral artery disease, pulmonary disea

224 ral artery disease and to explore associated claudication physiological mechanisms.

225 The classic manifestations are headache, jaw claudication, polymyalgia rheumatica (PMR), and visual s

226 presenting manifestations are headache, jaw claudication, polymyalgia rheumatica, and visual symptom

227 ess fractures, stress reaction, periostitis, claudication, popliteal artery entrapment, and periphera

228 among patients referred for biopsy were jaw claudication (positive likelihood ratio [LR], 4.2; 95% c

229 tion-specific rates of revascularization for claudication, postrevascularization progression from cla

230 ecific symptom severity measured with Zurich Claudication Questionnaire (ZCQ), back pain and leg pain

231 The San Diego Claudication Questionnaire assessed exertional leg pain.

232 ary outcome of disease-specific Intermittent Claudication Questionnaire score at 4 months (3.2 points

233 Secondary outcomes included the Zurich Claudication Questionnaire, leg and back pain scores, an

234 he ODI score as well as scores on the Zurich Claudication Questionnaire, leg and back pain, the durat

235 ive Revascularization or Not in Intermittent Claudication) randomized patients with mild-to-severe in

236 r in patients with stable lifestyle-limiting claudication receiving current medical management.

237 mities) with known or suspected intermittent claudication referred for lower extremity treadmill exer

238 sment, unselected patients with intermittent claudication requesting treatment for claudication were

239 ot revealed until symptoms like intermittent claudication, rest pain and ischemic gangrene develop, a

240 The intermittent claudication risk profile allows physicians to identify

241 am Heart Study, we developed an intermittent claudication risk profile.

242 hout asthma was associated with intermittent claudication (RRR:4.63, 95% CI:1.72-12.5), whereas no si

243 METHODS AND Patients with intermittent claudication secondary to peripheral artery disease who

244 attack or stroke, a history of intermittent claudication, stenosis of 80 to 94 percent of the lumina

245 obasilar insufficiency or,most commonly, arm claudication.Subclavian steal should be considered among

246 uestionnaire (EQ-5D) (score range, 0-1), and Claudication Symptom Instrument (CSI) (score range, 0-4)

247 Previously reported lack of worsening in claudication symptoms over time in patients with PAD may

248 remain the first-line medical therapies for claudication symptoms, and anticoagulants are added to p

249 For claudication symptoms, several newer drugs and the use o

250 in PAD participants with and without classic claudication symptoms.

251 Edema was less common in patients with claudication than in those with pain at rest (P = 0.016)

252 is most often manifested by mild symptoms of claudication that can be managed conservatively.

253 aim to enroll 320 patients with intermittent claudication that does not respond to medical management

254 Treatment for claudication that is due to aortoiliac peripheral artery

255 pheral arterial disease include intermittent claudication, that is, pain with walking, and critical l

256 tion, postrevascularization progression from claudication to CLTI, and rates of guideline-based risk-

257 te of postrevascularization progression from claudication to CLTI.

258 ed patients with mild-to-severe intermittent claudication to either revascularization + best medical

259 Progression from claudication to limb ischemia is infrequent.

260 Claudication treatment is increasingly being measured by

261 ns merits its consideration as a primary PAD claudication treatment.

262 Patients with claudication undergoing an index lower-extremity revascu

263 Patients with claudication undergoing early invasive treatment had gre

264 d total agreement (81.3%) for distinguishing claudication versus CLTI.

265 haracteristic findings include headache, jaw claudication, visual loss, and constitutional symptoms (

266 The presence of venous claudication was assessed by > or =3 independent examine

267 NM-702 used for 24 weeks by patients with claudication was associated with improvements in laborat

268 Among patients with PAD, classic claudication was distinctly uncommon (11%).

269 or cardiovascular prevention and symptoms of claudication was low: any antiplatelet therapy in 35.7%

270 % male, 37% with diabetes) with intermittent claudication were enrolled at medical centers affiliated

271 Black and Hispanic patients with claudication were more likely to have diabetes and be un

272 Two hundred eighty-nine patients with claudication were randomized in a double-blind manner to

273 ittent claudication requesting treatment for claudication were randomly assigned to invasive (n=79) o

274 may be considered for selected patients with claudication who fail endovascular therapy or are not ca

275 peripheral artery disease with intermittent claudication who have not responded to medical treatment

276 resentation; from patients with intermittent claudication who should undergo structured exercise reha

277 lasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral arter

278 lking ability and pressure indices in stable claudication, with a durable outcome.

279 heral artery disease experience intermittent claudication, with consequent loss of quality of life.

280 commended as the first line of treatment for claudication, with revascularization considered for trea